

PATENT
1662/466073

Listing of Claims:

Claims 1-19 (Canceled).

20. (Amended) A composition comprising a polydisperse mixture of polypeptides composed of glutamic acid, lysine, alanine and tyrosine, wherein the mixture has an average molecular weight of about 4 to about 9 kilodaltons, and wherein the mixture of polypeptides is non-uniform with respect to molecular weight and constitution.
21. (Previously presented) The composition of claim 20, wherein over 75% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight in a range of about 2 kilodaltons to about 20 kilodaltons.
22. (Previously presented) The composition of claim 20, wherein less than 5% of the polypeptides of the mixture have a molecular weight of over 40 kilodaltons.
23. (Previously presented) The composition of claim 22, wherein over 75% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight in a range of about 2 kilodaltons to about 20 kilodaltons.
24. (Previously presented) The composition of claim 23, wherein the mixture has an average molecular weight of 6.25 to 8.4 kilodaltons.
25. (Previously presented) The composition of claim 20, wherein the mixture has an average molecular weight of about 4 to about 8.6 kilodaltons.
26. (Previously presented) The composition of claim 20, wherein the mixture has an average molecular weight of about 5 to about 9 kilodaltons.

PATENT
1662/466073

27. (Previously presented) The composition of claim 20, wherein less than 2.5% of the polypeptides of the mixture have a molecular weight of over 40 kilodaltons.
28. (Previously presented) The composition of claim 27, wherein over 75% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight in a range of about 2 kilodaltons to about 20 kilodaltons.
29. (Previously presented) The composition of claim 28, wherein the mixture has an average molecular weight of 6.25 to 8.4 kilodaltons.
30. (Previously presented) The composition of claim 20, wherein the mixture has a molecular weight distribution substantially as depicted in the curves of Figure 1 or Figure 2 in which the average molecular weight is about 7.7 kDa.
31. (Previously presented) A pharmaceutical composition comprising a dose therapeutically effective to treat multiple sclerosis of the composition of any of claims 20-30.
32. (Previously presented) A method for treating a patient suffering from multiple sclerosis comprising administering to a patient in need thereof the composition of claim 31.